Compare Deere & Company (DE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs BIO-TECHNE Corp — how do they compare? Deere & Company trades at $652.58 (market cap $175.95B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Deere & Company is far larger — about 15.5× BIO-TECHNE Corp's market cap, and Deere & Company pays the higher dividend (0.99%). Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and BIO-TECHNE Corp for 63 Days on average.
| DE | TECH | |
|---|---|---|
Market Cap | $175.95B | $11.36B |
Volume | 1,387,231 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $709.48 | $72.61 |
52-Week Low | $439.11 | $43.31 |
Typical Hold Time | 75 Days | 63 Days |
Enterprise Value | $229.85B | $11.39B |
Dividend Yield | 0.99% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $656.87, down 3.8% on the day, reflecting near-term pressure amid a broader bearish technical signal. The stock has demonstrated strong earnings momentum, beating estimates in the last three quarters, but faces headwinds from declining revenue and net income margins. Recent news highlights the company's focus on AI-driven agricultural solutions to counter cyclical downturns, while analyst consensus remains divided with a price target of $731.20 suggesting potential upside from current levels.
The outlook for DE is mixed; solid profitability metrics and consistent cash flow generation support the investment case, but cyclical exposure to agriculture equipment demand and elevated valuation ratios pose risks. Earnings growth and successful execution of technology initiatives are key catalysts for outperformance, though macroeconomic volatility could dampen near-term returns.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
